Please assess the completion status of the following clinical trial:

Trial Title: A Study Comparing ARB With Radium-223 vs ARB Therapy With Placebo and the Effect Upon Survival for mCRPC Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~1. Able and willing to provide informed consent.~2. Histologically or cytologically confirmed diagnosis of prostate adenocarcinoma.~3. Men ≥ 18 years.~4. ECOG performance status of 0 or 1 at screening.~5. Metastatic to bone with ≥ 2 bone metastases (area of increased uptake on 99mTc bone scan); equivocal lesions on the bone scan must be confirmed by standard X-ray, CT, or MRI.~6. Patients must have progressive metastatic castration-resistant prostate cancer (mCRPC) at screening and on androgen deprivation therapy (ADT) as evidenced by either:~   1. For patients who manifest disease progression solely as a rising prostate-specific antigen (PSA) level - documentation of a sequence of two rising PSA values at a minimum of 1-week apart with the Screening value ≥1 ng/ml (see Appendix D);~  2. For patients with disease progression manifested in the bone, irrespective of progression by rising PSA - defined by the appearance of 2 or more new skeletal lesions demonstrated by 99Tc bone imaging. Ambiguous results should be confirmed by other imaging modalities than bone scan and x-ray (e.g.: CT-scan or MRI).~  3. For patients with disease progression manifested at nodal sites, irrespective of progression by rising PSA - progression defined per RECIST 1.1.~7. Ongoing ADT with luteinizing hormone-releasing hormone (LHRH) agonist or antagonist or bilateral orchiectomy.~8. Use of bone health agents (denosumab or zoledronic acid or other bisphosphonates) starting any time prior to R1 unless contraindicated or considered not in the best interest of the patient. A waiver must be approved by the medical monitor if bone health agents cannot be used. Bone health agents should be continued throughout both RT1 and RT2 treatment periods.~9. Adequate bone marrow and organ function as defined by:~   1. Hemoglobin ≥ 10.0 g/dL~  2. Absolute neutrophil count (ANC) ≥ 1.5 x 109/L~  3. Platelets ≥ 100 x 109/L~  4. Serum creatinine ≤ 1.95 mg/dL~  5. Estimated creatinine clearance \>/= 30 mL/min by Cockroft-Gault calculation~  6. Alanine aminotransferase (ALT) ≤ 175 U/L~  7. Aspartate aminotransferase (AST) ≤ 100 U/L~  8. Total bilirubin ≤ 1.8 mg/dL (unless the patient a diagnosis of Gilbert's disease or a similar syndrome involving slow conjugation of bilirubin; in patients with Gilbert's, the total bilirubin should be less than 6 mg/dL if patient has Gilbert's and the elevation should be seen in the unconjugated or indirect bilirubin measurement)~  9. LDH ≤ 224 U/L at screening.~  10. Albumin ≥ 2.5 g/dL~10. Fertile male patients, defined as all males physiologically capable of conceiving offspring with female partners of child-bearing potential, must be willing to use condoms plus spermicidal agent during the study treatment period and for 6 months after the last dose of study drug, and not father a child or donate sperm during this period.~11. The treating site investigator deems RT1 (Enzalutamide or Darolutamide) treatment safe and feasible.~    Subjects must meet the remaining inclusion criteria in order to be qualified for the second randomization (R2). Only subjects that complete the initial 12 weeks of run-in RT1 should be evaluated. Prior inclusion criteria do not need to be re-evaluated:~12. Patients must have a documented ≥ 30% decline of PSA at any time during the 12 weeks of RT1.~13. Patients must have no evidence of visceral metastatic disease at the time of RT2 randomization~14. Ongoing treatment with RT1 and bone health agents at time of RT2 randomization.~15. The treating site investigator deems RT2 (Ra-223 dichloride) treatment safe and feasible.~Exclusion Criteria:~1. Pathological finding consistent with small cell carcinoma of the prostate.~2. Prior chemotherapy for CRPC. Prior docetaxel for hormone-sensitive disease is permitted under the following conditions: started within 3 months of ADT initiation, given for a maximum of 6 cycles and progression occurred \> 6 months after the last dose of docetaxel.~3. Prior treatment for mCRPC or CRPC. However, the following therapies are permitted and not exclusionary: Sipuleucel-T, 5-alpha-reductase inhibitors, estrogens, or older antiandrogens (such as flutamide, bicalutamide, or nilutamide).~4. Prior treatment for more than 2 months with CYP17 inhibitors (e.g. abiraterone or orteronel).~5. Prior treatment for more than 2 months with agents inhibiting androgen receptor signaling (e.g. enzalutamide, apalutamide, or darolutamide).~6. Prior hemibody or whole-body external radiotherapy. Other types of prior external radiotherapy and brachytherapies are allowed.~7. Prior therapy with radionuclides (e.g., radium-223, strontium-89, samarium-153, rhenium-186, rhenium-188, actinium-225 and lutetium-177).~8. Current involvement in any drug or device trial involving investigational agent or medical device within the last 28 days prior to R1.~9. In general, any prior investigational agent for nmCRPC/mCRPC; however, may be reviewed by medical monitor/PIs for waiver consideration, on a case-by-case basis.~10. Hypersensitivity to compounds related to enzalutamide, darolutamide, or Ra-223.~11. A blood transfusion ≤ 28 days prior to R1.~12. Major surgical procedures ≤ 28 days or minor surgical procedures ≤7 days prior to R1. No waiting period is required following port-a-cath placement.~13. Patients with visceral metastases, clinical evidence of central nervous system metastases, or leptomeningeal tumor spread as demonstrated via CT/MRI of chest, abdomen, pelvis, and CNS (if needed). CT/MRI of the CNS only performed if suspicion of CNS metastases or leptomeningeal tumor spread. Nodules \< 1 cm alone will not be considered visceral metastases. Renal masses \< 3 cm will not be considered exclusionary.~14. Serious active infection at the time of screening or another serious underlying medical condition that would impair the ability of the patient to receive protocol treatment.~15. Presence of other active cancers, or history of treatment for invasive cancer ≤2 years of R1. Patients with Stage I/II cancer who have received definitive local treatment and are considered unlikely to recur are eligible. All patients with previously treated in situ carcinoma (i.e., non-invasive) and superficial bladder cancer are eligible, as are patients with history of non-melanoma skin cancer.~16. Any other serious or unstable illness, or medical, social, or psychological condition, that could jeopardize the safety of the subject and/or his/her compliance with study procedures, or may interfere with the subject's participation in the study or evaluation of the study results.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Enzalutamide during Lead-in Period (Type: OTHER): Randomized, open-label lead-in ARB (enzalutamide tablets, 160 mg PO QD) for 12 weeks.
- Lead-in Enzalutamide followed by Radium-223/Enzalutamide (Type: ACTIVE_COMPARATOR): Randomized, open-label lead-in ARB (enzalutamide) for 12 weeks followed by randomized, double-blind Radium-223 IV at 55 kBq/kg IV up to 6 cycles (at 4 week intervals) with continued randomized open-label enzalutamide.
- Lead-in Enzalutamide followed by Placebo/Enzalutamide (Type: PLACEBO_COMPARATOR): Randomized, open-label lead-in ARB (enzalutamide) for 12 weeks followed by randomized, double-blind normal saline placebo IV up to 6 cycles (at 4 week intervals) with continued randomized open-label enzalutamide.
- Darolutamide during Lead-in Period (Type: OTHER): Randomized, open-label lead-in ARB (darolutamide tablets, 300 mg PO BID) for 12 weeks.
- Lead-in Darolutamide followed by Radium-223/Darolutamide (Type: ACTIVE_COMPARATOR): Randomized, open-label lead-in ARB (darolutamide) for 12 weeks followed by randomized, double-blind Radium-223 IV at 55 kBq/kg IV up to 6 cycles (at 4 week intervals) with continued randomized open-label darolutamide.
- Lead-in Darolutamide followed by Placebo/Darolutamide (Type: PLACEBO_COMPARATOR): Randomized, open-label lead-in ARB (darolutamide) for 12 weeks followed by randomized, double-blind normal saline placebo IV up to 6 cycles (at 4 week intervals) with continued randomized open-label darolutamide.

Based on this trial design, predict the completion outcome and termination type (if applicable).